Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Summit Therapeutics Inc.SMMT · Entity 3477 | Chief Clinical Affairs Officer | October 04, 2020 | October 07, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Summit Therapeutics Inc.
Report date October 04, 2020 · Filed October 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.34 · Expires 2030-10-04 | Direct | 400,000 |
Reported balance
After 2020-10-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-04 · Grant · Acquired 400,000 · Balance 400,000 F1: The option was granted on October 4, 2020 pursuant to the Company's 2020 Stock Incentive Plan. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on October 4, 2021, subject to the satisfaction of certain performance targets. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on October 4, 2020 pursuant to the Company's 2020 Stock Incentive Plan. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on October 4, 2021, subject to the satisfaction of certain performance targets.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 04, 2020 Filed Oct 7, 2020 23:47 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 400,000 | $3.34 Strike: $3.34 | $1,336,000.00 |
DisclosureSEC source: 0000921895-20-002557 · form412566002_10072020.xml · derivative · entry 1 Graham Camilla · CIK 0001827543 · Chief Clinical Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2030-10-04 F1 · derivative.exercise_date: The option was granted on October 4, 2020 pursuant to the Company's 2020 Stock Incentive Plan. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on October 4, 2021, subject to the satisfaction of certain performance targets. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.